Three Synergistic Business Development Paths

PATH ONE

Developing, licensing and commercializing cannabinoid based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries.

Our intent is that any medications we develop will be physician prescribed.

PATH TWO

The developing or licensing of proprietary delivery systems for cannabinoid-based medications. The Company’s 1st technology, XactDose, provides for the accurate dosing of cannabinoid-based medications for both humans and animals.

PATH THREE

Investments in companies, and the acquisition of technologies, or medications, focused on cannabinoid-based research, through Special Purpose Vehicles (SPV) controlled by Nexien BioPharma Inc.

Our Team

teams Chief Executive Officer

Alex Wasyl

Chief Executive Officer, Nexien BioPharma Inc

  • CEO/Co-Founder, CRx Bio Holdings
  • Managing Director, Elevated Life Sciences
  • BS from The College of New Jersey
teams Executive Chairman of the Board and Chief Strategy Officer

Alain Bankier

Executive Chairman of the Board and Chief Strategy Officer, Nexien BioPharma Inc

  • Managing Partner/Co-Founder, VSTechVentures
  • Co-President/CEO, The Manischewitz Company
  • Partner in Ceylon Solutions, LLC
  • BS from the Wharton School, BA from the University of Pennsylvania and an MBA from NYU Stern and from HEC Paris
teams Chief Operating Officer

Robert I. Goldfarb

Chief Operating Officer, Nexien BioPharma Inc

  • Senior President/General Counsel, Andrx Corporation
  • General Counsel, Accubreak Inc
  • Partner, Hughes, Hubbard and Read
  • BA from University of Connecticut, J.D. from University of Florida
teams Chief Financial Officer

Evan Wasoff CPA

Chief Financial Officer, Nexien BioPharma Inc

  • CFO, Falcon Oil & Gas Ltd
  • Principal, AZCO Financial Mgmt LLC
  • CFO, Kantiva Inc
  • BS from State University of NY, MBA from University Of Colorado, Boulder
teams VP - Corporate Development

Frank J Manganella

VP - Corporate Development, Nexien BioPharma Inc

  • Managing Partner/Co-Founder, CH3 Ventures
  • Interim CFO/Managing Partner, CRx Bio Holdings
  • CEO/Founder, CH3 Partners
  • MBA from Durham University Business School in the UK
teams VP - Legal & Intellectual Property Counsel

Dr. Joseph Aceto, JD, PhD.

VP - Legal & Intellectual Property Counsel, Nexien BioPharma Inc

  • Counsel, Obermayer Rebmann Maxwelll and Hippel LLP
  • General Counsel/Managing Partner, CRx Bio Holdings
  • Board of Directors, Pennsylvania Drug Discovery Institute
  • MS from Drexel, Ph.D from the Lewis Katz School of Medicine Temple University and J.D. from the Widener University School of Law
teams VP - Translational Research

Jeremy Reeh, MB, MBA

VP - Translational Research, Nexien BioPharma Inc

  • Chief Scientific Officer/Co-Founder, CRx Bio Holdings
  • Outsourcing Consultant/Assignment, Daiichi Sankyo
  • Strategic Sourcing Manager, Johnson and Johnson
  • BAgrSc from Penn State, MB from the University of Pennsylvania and an MBA from Penn State

News